FibroGen, Inc (FGEN) Q3 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Hello, and thank you for standing by. Welcome to FiberGen Third Quarter 2025 Earnings Conference Call. At this time, all participants are on a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press Start 11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press Start 11 again. I would now like to hand the conference over to Gaia Seamus. You may begin. Thank you, Amanda. Good afternoon, everyone, and thank you for joining us today to discuss FibroGen's third quarter 2025 financial and business results. I'm Gaia Chamis from Lysa Advisors. Joining me on today's call are Thayne Wettig, Chief Executive Officer, and David DeLucia, Chief Financial Officer. Following the prepared remarks, we will open the call to your questions. I would like to remind you that remarks made on today's call include forward-looking statements about FibroGen. Such statements may include, but are not limited to, collaboration with AstraZeneca and Astellas, financial guidance, the initiation, enrollment, design, conduct, and results of clinical trials, regulatory strategies, and potential regulatory results, research and development activities, commercial results and results of operations, risks related to our business, and certain other business matters. Each forward-looking statement is subject to risks and uncertainties that could cause actual results and events to differ materially from those projected in that statement. A more complete description of these and other materials risks can be found in FibroGEN's filing with the SEC, including our most recent Form 10-K and Form 10-Q. FibroGen does not undertake any obligati...